u-100480 and Buruli-Ulcer

u-100480 has been researched along with Buruli-Ulcer* in 1 studies

Other Studies

1 other study(ies) available for u-100480 and Buruli-Ulcer

Article	Year
Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:3 Rifampin (RIF) plus clarithromycin (CLR) for 8 weeks is now the standard of care for Buruli ulcer (BU) treatment, but CLR may not be an ideal companion for rifamycins due to bidirectional drug-drug interactions. The oxazolidinone linezolid (LZD) was previously shown to be active against Topics: Animals; Anti-Bacterial Agents; Buruli Ulcer; Clarithromycin; Disease Models, Animal; Female; Linezolid; Mice; Mice, Inbred BALB C; Mycobacterium ulcerans; Oxazolidinones; Rifampin; Tetrazoles	2019

Article

Year

Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.

Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:3

Rifampin (RIF) plus clarithromycin (CLR) for 8 weeks is now the standard of care for Buruli ulcer (BU) treatment, but CLR may not be an ideal companion for rifamycins due to bidirectional drug-drug interactions. The oxazolidinone linezolid (LZD) was previously shown to be active against

Topics: Animals; Anti-Bacterial Agents; Buruli Ulcer; Clarithromycin; Disease Models, Animal; Female; Linezolid; Mice; Mice, Inbred BALB C; Mycobacterium ulcerans; Oxazolidinones; Rifampin; Tetrazoles

2019